- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05316220
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Mesalamine Delayed-release Capsules in Children Aged 5 to 17 Years for the Maintenance of Remission of Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) characterized by diffuse, continuous inflammation of the colon. This study will assess how safe and effective mesalamine delayed-release capsules are in treating pediatric participants with UC. Adverse events and change in disease activity will be assessed.
Delzicol (Mesalamine) is an approved drug being developed for the treatment of Ulcerative Colitis (UC). Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. Around 80 Pediatric participants aged 5 to 17 years with a diagnosis of UC will be enrolled in approximately 45 sites in the United States.
Participants will receive oral mesalamine capsules twice daily for 26 weeks and followed for 30 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: ABBVIE CALL CENTER
- Phone Number: 844-663-3742
- Email: abbvieclinicaltrials@abbvie.com
Study Locations
-
-
-
Caguas, Puerto Rico, 726
- San Juan Bautista School of Medicine /ID# 243377
-
San Juan, Puerto Rico, 912
- Centro de Investigaciones Clinicas San Jorge Children's and Women's Hospital /ID# 244595
-
-
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010-2916
- Childrens National /ID# 243379
-
-
Florida
-
Jacksonville, Florida, United States, 32225-3131
- Angel Kids Pediatrics /ID# 244874
-
-
Georgia
-
Atlanta, Georgia, United States, 30315
- Treken Primary Care /ID# 241302
-
Contact:
- Site Coordinator
- Phone Number: 4043050004
-
-
Illinois
-
Chicago, Illinois, United States, 60621
- Eagle Clinical Research /ID# 242045
-
-
Maryland
-
Silver Spring, Maryland, United States, 20910
- Virgo Carter Pediatrics /ID# 241556
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- UH Cleveland Medical Center /ID# 243375
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Children's Hospital Oklahoma /ID# 242614
-
-
Virginia
-
Roanoke, Virginia, United States, 24014
- Carilion Medical Center /ID# 244398
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Documented history of Ulcerative Colitis (UC) who have been successfully maintained in remission for at least 30 days prior to the screening visit and are on a stable dose of mesalamine or 5-aminosalicylic acid equivalent.
Exclusion Criteria:
- Abnormal and clinically significant results according to the investigator or designee, on physical examination, medical history, electrocardiogram (ECG), hematology, clinical chemistry, or urinalysis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mesalamine Dose A
Participants will receive mesalamine Dose A twice daily for 26 weeks.
|
Oral Capsules
Other Names:
|
Experimental: Mesalamine Dose B
Participants will receive mesalamine Dose B twice daily for 26 weeks.
|
Oral Capsule
Oral Capsules
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Maintaining Clinical Remission Responder Status Based on the modified Mayo Score (mMS)
Time Frame: Week 26
|
Clinical remission responder based on the mMS is defined as Endoscopy subscore = 0 or 1, AND Rectal bleeding subscore = 0, AND Stool frequency subscore <= 1.
|
Week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Maintaining Endoscopic Remission Responder Status Based on the mMS
Time Frame: Week 26
|
Endoscopic remission responder based on the mMS is defined as Endoscopy subscore = 0 or 1.
|
Week 26
|
Percentage of Participants Maintaining Symptomatic Remission Responder Status Based on the mMS
Time Frame: Week 26
|
Symptomatic remission responder based on the mMS s defined as Rectal bleeding subscore = 0 AND Stool frequency subscore <= 1.
|
Week 26
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: ABBVIE INC., AbbVie
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Gastrointestinal Diseases
- Gastroenteritis
- Colonic Diseases
- Intestinal Diseases
- Inflammatory Bowel Diseases
- Ulcer
- Colitis
- Colitis, Ulcerative
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Mesalamine
Other Study ID Numbers
- M21-517
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis (UC)
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingUlcerative Colitis (UC)China
-
AbbVieActive, not recruitingUlcerative Colitis (UC)United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, New... and more
-
AbbVieCompletedUlcerative Colitis (UC)United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Nether... and more
-
AbbVieCompletedUlcerative Colitis (UC)United States, Canada, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom
-
AbbVieCompletedUlcerative Colitis (UC)United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea,... and more
-
Liaocheng People's HospitalUnknownUlcerative Colitis (UC)China
-
TLA, Targeted Immunotherapies ABRecruitingUlcerative Colitis (UC)Sweden
-
AbbVieActive, not recruitingUlcerative Colitis (UC)United States, Australia, Austria, Belgium, Canada, Croatia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Mexico, Netherlands, New Zealand, Norway, Puerto Rico, Spain, Sweden, United Kingdom
-
Theravance BiopharmaTerminatedUlcerative Colitis (UC)United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
-
AbbVieCompletedUlcerative Colitis (UC)United States, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Romania, Slovakia, Spain, Switzerland, Ukraine, United Kingdom
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States